Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome

BACKGROUND: Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial overgrowth (SIBO), few data are available regarding its efficacy in non-IB...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Boltin, Doron, Perets, Tsachi Tsadok, Shporn, Einav, Aizic, Shoshana, Levy, Sigal, Niv, Yaron, Dickman, Ram
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2014
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201689/
https://ncbi.nlm.nih.gov/pubmed/25319626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-014-0049-x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים